Skip to content

Precision for Medicine, GmbH CIR (French Research Tax Credit) Accreditation Updates

Precision’s German Entity Celebrates Renewal of French Research Tax Credit (CIR) Accreditation for 2023-2025

Berlin, Germany - February 20, 2024 - Precision for Medicine, GmbH, the distinguished German entity of Precision for Medicine, proudly announces the renewal of its accreditation under the French Research Tax Credit (‘Crédit d’Impôt Recherche’, CIR) program by the French Ministry of Higher Education and Research (MESR). This esteemed accreditation, extended for the period 2023 through 2025, affirms Precision for Medicine's unwavering commitment to facilitating high-impact research and development in the life sciences sector.

The French R&D tax credit initiative (‘Crédit d’Impôt Recherche’, CIR) gives eligible research-based French companies, who are subject to corporate tax in France, the ability to claim tax relief on costs generated in R&D activities outsourced to Precision for Medicine.1, 2

Under this accreditation, the French Ministry of Higher Education and Research has also recognized Precision for Medicine’s Italian, Polish, German, Spanish, and Hungarian affiliates as reputable cross-border R&D experts.

We are thrilled to receive this accreditation as it allows our current and future clients in France to benefit from a tax relief of up to 30% of their R&D expenditure committed to Precision for Medicine.

Andrea Cotton-Berry, Precision for Medicine’s Global Head of Strategic Development


Implications for Precision and Its Clients

The CIR accreditation renewal not only reinforces Precision for Medicine’s role as a leader in precision medicine but also underscores the financial and innovative benefits available to its French clients. By leveraging this accreditation, clients are empowered to pursue groundbreaking research endeavors, accelerating the development of novel healthcare solutions while optimizing financial resources.

As Precision for Medicine, GmbH looks to the future, we are excited to deepen our engagement with French clients, driving forward our shared mission to advance the field of precision medicine. We remain dedicated to delivering exceptional research services that adhere to the rigorous standards set by the French government and exceed the expectations of our clients.

About Precision for Medicine

Precision for Medicine supports life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies novel biomarker approaches to clinical research that take advantage of the latest advancements in science and technology, focusing predominantly on genomics, immune-response assays, global specimen logistics, biomarker analytics, companion diagnostics, and clinical trial execution. Precision for Medicine is part of Precision Medicine Group, with over 3,000 employees in 40 locations across North America, Europe and APAC. For more information, visit